- $275.72m
- $259.75m
- $4.76m
- 47
- 11
- 88
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.46 | ||
| Price to Tang. Book | 3.46 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 48.97 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -18.97% | ||
| Return on Equity | -45.8% | ||
| Operating Margin | -665.67% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 18.37 | 29.39 | 38.16 | 6.03 | 4.76 | 20.99 | 26.97 | -2.13% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -13.44 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Directors
- James Neal CHM (65)
- Thomas Burns CFO (47)
- W. Denman Van Ness LED (78)
- Heather Franklin IND (54)
- Natasha Hernday IND (49)
- Barbara Kosacz IND (63)
- Joseph Limber IND (68)
- Matthew Perry IND (48)
- Jack Wyszomierski IND (65)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- December 31st, 2011
- Public Since
- June 6th, 1986
- No. of Shareholders
- 188
- No. of Employees
- 13
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 11,638,553
- Address
- Suite 310, 2200 Powell Street, EMERYVILLE, 94608
- Web
- https://www.xoma.com/
- Phone
- +1 5102047239
- Auditors
- Deloitte & Touche LLP
Upcoming Events for XOMA
Dividend For XOMAO.OQ - 0.5234 USD
Q2 2024 XOMA Corp Earnings Release
Q3 2024 XOMA Corp Earnings Release
Similar to XOMA
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the XOMA share price?
As of Today at 24:13 UTC, shares in XOMA are trading at $24.45. This share price information is delayed by 15 minutes.
How has the XOMA share price performed this year?
Shares in XOMA last closed at $24.45 and the price had moved by +26.36% over the past 365 days. In terms of relative price strength the XOMA share price has outperformed the S&P500 Index by +0.54% over the past year.
What are the analyst and broker recommendations for XOMA?
The overall consensus recommendation for XOMA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the XOMA dividend yield?
XOMA does not currently pay a dividend.
Does XOMA pay a dividend?
XOMA does not currently pay a dividend.
When does XOMA next pay dividends?
XOMA does not currently pay a dividend.
How do I buy XOMA shares?
To buy shares in XOMA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of XOMA?
As of the previous close price of $24.45, shares in XOMA had a market capitalisation of $284.56m.
Where are XOMA shares listed?
Here are the trading details for XOMA:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: XOMA
What kind of share is XOMA?
Based on an overall assessment of its quality, value and momentum XOMA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a XOMA share price forecast for 2024?
The analyst consensus target price for shares in XOMA is $58.00. That is 137.22% above the last closing price of $24.45.
Analysts covering XOMA currently have a consensus Earnings Per Share (EPS) forecast of -$1.89 for the next financial year.
What is the trend in the XOMA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like XOMA. Over the past six months, its share price has outperformed the S&P500 Index by +16.11%.
As of the last closing price of $24.45, shares in XOMA were trading +18.19% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the XOMA PE Ratio?
The XOMA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $24.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of XOMA?
XOMA's management team is headed by:
- James Neal - CHM
- Thomas Burns - CFO
- W. Denman Van Ness - LED
- Heather Franklin - IND
- Natasha Hernday - IND
- Barbara Kosacz - IND
- Joseph Limber - IND
- Matthew Perry - IND
- Jack Wyszomierski - IND